Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NantHealth, Inc.NH · Entity 109592 | Director | June 09, 2022 | June 10, 2022 |
| PLx Pharma Inc.PLXP · Entity 129056 | Director | February 22, 2022 | February 24, 2022 |
| Ryerson Holding CorpRYZ · Entity 4782 | Director | July 23, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NantHealth, Inc.
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2032-06-09 | Direct | 100,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date.
PLx Pharma Inc.
Report date February 22, 2022 · Filed February 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2032-02-22 | Direct | 20,000 |
Reported balance
After 2022-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-22 · Grant · Acquired 20,000 · Balance 20,000 F1: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended. F2: These stock options vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended.
F2: These stock options vest in full on the first anniversary of the grant date.
Ryerson Holding Corp
Report date July 23, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (par value $0.01 per share)SEC Table I · non-derivative | Direct | 4,673 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Grant · Acquired 97 · Balance 4,673 F1: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 28, 2026 00:28 UTC | Ryerson Holding Corp RYZ · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 97 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-26-000735 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,673 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 00:44 UTC | Ryerson Holding Corp RYZ · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 389 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-26-000383 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,576 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 22:05 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 347 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-26-000020 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,187 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 21:00 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 382 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-25-001152 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,840 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 23:03 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 405 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-25-000805 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,458 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 22:42 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 381 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-25-000513 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,053 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:18 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 472 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-25-000014 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,672 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 01:47 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 439 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111087 · ownership.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:18 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 448 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-080949 · ownership.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,761 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 21:22 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value ($0.01 per share) | 261 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-24-000420 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,313 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 21:11 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value $0.01 per share) | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-24-000050 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 21:13 UTC | Ryerson Holding Corp RYI · Entity 4782 | GrantCommon Stock (par value ($0.01 per share) | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-23-000971 · form4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 F1 · shares: Reflects compensation in the form of equity received pursuant to Ryerson's Director Compensation Program. The award vested in full on the grant date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:28 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000899243-22-021906 · doc4.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 20:11 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0000921895-22-000659 · form411577cal_02242022.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended. F2 · derivative.exercise_date: These stock options vest in full on the first anniversary of the grant date. Read SEC document |
| June 16, 2021 Filed Jul 26, 2021 22:04 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0000899243-21-029927 · doc4.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 19:32 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000921895-20-003079 · form411577002cal_11202020.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-11-18 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan. F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0000899243-20-014193 · doc4.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:47 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0000921895-20-000900 · form411577002cal_03242020.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-03-20 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan. F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 23:32 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 301,908 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-19-017240 · doc4.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,908 Underlying: Common Stock · 301,908 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:58 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0000921895-19-000812 · form411577cal_03182019.xml · derivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-14 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan. F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:47 UTC | NantHealth, Inc. NH · Entity 109592 | GrantCommon Stock | 52,910 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024008 · doc4.xml · nonDerivative · entry 2 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,780 F1 · security: Each restricted stock unit ("RSU") is the economic equivalent of one share of NantHealth, Inc. common stock. F3 · shares: The RSUs shall vest on the earlier of (i) the one year anniversary of the date the RSU award is granted, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, in each case, subject to the Reporting Person's continuing to be a service provider (as defined in the 2016 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:47 UTC | NantHealth, Inc. NH · Entity 109592 | GrantCommon Stock | 45,002 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024008 · doc4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,870 F1 · security: Each restricted stock unit ("RSU") is the economic equivalent of one share of NantHealth, Inc. common stock. F2 · shares: Subject to the Reporting Person's continuing to be a service provider (as defined in the 2016 Equity Incentive Plan) through each applicable vesting date, 33,751 RSUs shall be vested as of September 6, 2018, and the remaining 11,251 RSUs shall vest in installments as follows: 3,750 RSUs shall vest on each of December 7, 2018 and March 7, 2019, and 3,751 RSUs shall vest on June 7, 2019. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:15 UTC | NantHealth, Inc. NH · Entity 109592 | GrantCommon Stock | 50,868 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025615 · doc4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,868 F1 · security: Each restricted stock unit ("RSU") is the economic equivalent of one share of NantHealth, Inc. common stock. F2 · shares: Subject to the Reporting Person's continuing to be a service provider (as defined in the 2016 Equity Incentive Plan) through each applicable vesting date, 21,195 RSUs shall be vested as of November 6, 2017, and the remaining 29,673 RSUs shall vest in equal installments on each three-month anniversary of the Vesting Commencement Date over a period of twenty-one (21) months after the Vesting Commencement Date (i.e., 4,239 RSUs shall vest on each of December 7, 2017, March 7, 2018, June 7, 2018, September 7, 2018, December 7, 2018, March 7, 2019 and June 7, 2019). Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 21:14 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantOptions · Derivative | 9,002 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001144204-17-021378 · v464774_4.xml · derivative · entry 2 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,002 Underlying: Common Stock · 9,002 shares Expires 2025-07-22 F2 · shares: Received in connection with the Merger in exchange for an employee stock option to buy 11,429 shares of PLx Opco Inc. common stock for $9.80 per share. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 21:14 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-021378 · v464774_4.xml · nonDerivative · entry 1 CALHOUN KIRK K · CIK 0001203721 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675 F1 · price: Received in exchange for 2,089 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.